BRING THIS TO YOUR DOCTOR · GREY PEPTIDES

Anidulafungin

Also called: Eraxis; VER002; LY303366

What it is

A daily intravenous echinocandin approved as Eraxis (2006) for candidaemia, other Candida infections and esophageal candidiasis.

Approval status

FDA Approved. Approved in the US as Eraxis, NDA 021632, on February 17, 2006 (Drugs@FDA via openFDA and the Eraxis label effective August 19, 2025, read October 3, 2026).

Dosing, as printed in the page's Recommended Dosing box

Manufacturer's recommended dosing (FDA label)

From the prescribing information. Other doses studied, if any, are in the full dosing data below.

Protocol and source	Dose	Frequency	Duration	Route
Label: candidaemia and other Candida infections, adults **[Approved label]** Eraxis (anidulafungin) for injection US prescribing information (DailyMed set a88d9010, effective August 19, 2025)	200 mg loading dose, then 100 mg	Once daily	At least 14 days after the last positive culture	Intravenous
Label: oesophageal candidiasis, adults **[Approved label]** Eraxis (anidulafungin) for injection US prescribing information (DailyMed set a88d9010, effective August 19, 2025)	100 mg loading dose, then 50 mg	Once daily	At least 14 days, and 7 days after symptoms resolve	Intravenous
Label: candidaemia, children 1 month and older **[Approved label]** Eraxis (anidulafungin) for injection US prescribing information (DailyMed set a88d9010, effective August 19, 2025)	3 mg/kg (max 200 mg) loading, then 1.5 mg/kg (max 100 mg)	Once daily	At least 14 days after the last positive culture	Intravenous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for "research use only" are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

Key human evidence

The first 3 of the 11 human studies carded on the page (11 study cards in all):

• **Against fluconazole for invasive candidiasis** (Human, 2007). In 245 patients, 89% with candidaemia only, treatment success at the end of intravenous therapy was 75.6% on anidulafungin against 60.2% on fluconazole (difference 15.4 points, 95% CI 3.9 to 27.0). **PMID 17568028**

• **Esophageal candidiasis** (Human, 2004). In 601 patients, endoscopic success was 97.2% on intravenous anidulafungin and 98.8% on oral fluconazole, meeting noninferiority; treatment-related adverse events were 9.3% against 12.0%. **PMID 15472806**

• **Children aged 2 to 17** (Human, 2019). In an open-label study of 49 children with invasive candidiasis, all had at least one treatment-emergent adverse event (most often vomiting, diarrhoea and fever), 4 stopped for drug-related events, and all-cause mortality was 14.3% by week 6. **PMID 30418357**

Interactions

From the FDA label's drug-interaction section (Pfizer. ERAXIS (anidulafungin) US prescribing information, section 7. DailyMed version of August 19, 2025, read October 3, 2026):

• With cyclosporine, voriconazole, tacrolimus: no significant change in either drug; no dose adjustment (FDA label)

• With rifampin, liposomal amphotericin B: no significant change in anidulafungin; no dose adjustment (FDA label)

Side effects and cautions

Reported side effects	Contraindications and cautions
• Treatment-related adverse events in 9.3% against 12.0% on fluconazole in the esophageal trial	• Liver adverse reactions • Anaphylaxis and hypersensitivity reactions • Neonatal toxicity from polysorbates • Risk in hereditary fructose intolerance

Five questions to ask

1. Is Anidulafungin right for me, and is the labelled dose on this sheet right for my weight, age, kidney and liver function?
2. Here are the medicines and supplements I take. Do any of them interact with Anidulafungin? This sheet lists the interactions on record.
3. Which side effects should make me stop and call you, for example treatment-related adverse events in 9.3% against 12.0% on fluconazole in the esophageal trial?
4. Do any of the cautions on this sheet apply to me, such as: Liver adverse reactions?
5. What should we check before I start and while I am on it (blood tests, blood pressure, weight), and how often?

Grey Peptides is a vendor-neutral encyclopedia: it sells nothing and names no seller. This sheet is educational, not medical advice, and is not a prescription.